Rimoslim is the generic version of Acomplia and works in the endocannabinoid system located in the brain. The Endocannabinoid system is one that affects glucose and fat metabolism, energy balance and body weight. The drug affects the activity on the CB 1 receptors in the endocannabinoid system. These receptors control and regulate nicotine and food intake. By reducing the CB 1 receptors activity Rimoslim (Acomplia) causes patients to have a feeling of no longer wanted to eat. There is therefore a suppression of the appetite. Rimoslim reduces the CB 1 receptors activity by blocking them.
When Rimoslim is used along with a diet low in calories and regular exercise at a moderate level, Rimoslim will cause a dramatic loss of weight in patients who are obese.
Rimoslim is used mainly for the treatment of obesity and overweight, but it also has the effect of reducing the urge to take tobacco, that most smokers have. The end result will be that Rimoslim causes you eat less and also reduce smoking.

When Rimoslim is used as a treatment for obesity it is given mainly to people who are overweight which are those with a Body Mass Index more than or equal to 30 kg/m2 Rimoslim is also given to overweight people who are susceptible to medical risk factors such as heart disease.

For anyone who is obese and who would like to take Rimoslim you should have a meeting with your physician to talk about the drug as a therapeutic treatment choice and if it is right for you.